Market
CereVasc Rakes In $85M to Challenge Traditional Brain Shunt Surgery
CereVasc closed an $85 million Series C funding round to support development of its eShunt system, a minimally invasive alternative to conventional brain shunt surgery for hydrocephalus treatment. The company expects to complete a pivotal clinical trial and submit to the FDA in 2027.
The source
This brief is a MedIndexer summary of reporting by MedCity News. To read the full story, head to the source.
Read the full story at MedCity News